Lyra Therapeutics Inc (LYRA)
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company listed on OTC Markets as common stock. The company is developing therapies for chronic rhinosinusitis, with a focus on anti-inflammatory treatments. Its delivery approach is designed to place medicine at the target tissue and provide extended exposure from a single administration. Lyra’s pipeline includes LYR-210, an implantable drug matrix in Phase III testing for chronic rhinosinusitis, and LYR-220, which is being studied for patients who have not responded adequately to prior medical therapy. The company also has a collaboration with LianBio Inflammatory Limited covering development and commercialization rights for LYR-210 in several Asian markets, including mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Founded in 2005, Lyra Therapeutics is headquartered in Watertown, Massachusetts, and previously operated under the name 480 Biomedical, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-LYRA
|
$0.63
|
20.6% Upside
|
Undervalued
|
$16 2,976.9% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
0.0x
|
-0.1x
|
2.3x
|
922.938 K
|
15.289 M
|
97.0%
|
18.9%
|
-19.3
|
—
|
100.2%
|
